Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response. An AISF RECOLT-C Group Study
Document title: Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response. An AISF RECOLT-C Group Study
Journal: Annals of hepatology
Database: PERIÓDICA
System number: 000417067
ISSN: 1665-2681
Authors: 1
1
1
1
2
3
4
5
6
7
8
9
10
6
1
Institutions: 1Universita Cattolica di Roma, Policlinico A. Gemelli, Roma, Lazio. Italia
2Ospedale Niguarda Ca’ Granda, Milán, Lombardia. Italia
3Policlinico di Milano, Milán, Lombardia. Italia
4Policlinico Sant'Orsola-Malpighi, Bolonia, Emilia Romaña. Italia
5Ospedale San Camillo-Spallanzani, Roma, Lazio. Italia
6Ospedale Riuniti di Bergamo, Bergamo, Lombardia. Italia
7Universita di Bari, Bari, Puglia. Italia
8Universita degli Studi di Roma "Tor Vergata", Roma, Lazio. Italia
9Universita di Modena e Reggio Emilia, Módena. Italia
10Universita di Udine, Udine, Friuli Venezia Giuli. Italia
Year:
Season: May-Jun
Volumen: 11
Number: 3
Pages: 338-342
Country: México
Language: Inglés
Document type: Artículo
Approach: Analítico, descriptivo
English abstract Hepatitis C virus genotype 4 is predominant in the Middle East and Northern Africa, even if it has recently spread to Southern Europe. Data about the treatment of post-liver transplantation (LT) genotype 4 hepatitis C recurrence are scarce. We report a retrospective analysis of post-LT genotype 4 hepatitis C treatment in 9 Italian transplant centres, focusing on the overall survival rates and treatment outcome. Results. Among 452 recipients, we identified 17 HCV genotype 4 patients (16 males, 1 female) transplanted between 1998 and 2007. All patients received combined antiviral treatment with conventional doses of interferon (recombinant or pegylated) and ribavirin after histological diagnosis of hepatitis C recurrence. The observed overall survival after LT was 100% at 1 year and 83.3% at 5 years. More than 1/3 (35.3%) of patients achieved a sustained virological response (SVR) and 40% (data available in 15 subjects) an early virological response (EVR), which was significantly associated with the achievement of SVR (overall accuracy: 85.7%; predictive values of EVR absence/presence 80/88.8%; chi-square p < 0.05). Conclusion. In conclusion, in post-LT genotype 4 hepatitis C treatment, SVR rates are similar to genotype 1. Patients who don’t show an EVR are not likely to achieve a SVR
Disciplines: Medicina
Keyword: Gastroenterología,
Terapéutica y rehabilitación,
Hepatitis C,
Trasplante de hígado,
Virus de la hepatitis C,
Recurrencia,
Genotipificación
Keyword: Gastroenterology,
Therapeutics and rehabilitation,
Hepatitis C,
Liver transplantation,
Hepatitis C virus,
Recurrence,
Genotyping
Full text: Texto completo (Ver PDF)